A Study Of Muscarinic Receptors In Brain Tissue Obtained Postmortem From Subjects With Schizophrenia
Funder
National Health and Medical Research Council
Funding Amount
$354,810.00
Summary
The research outlined in this proposal will examine the molecular make up of certain regions of the human brain and determine if components within those regions are altered in tissue from subjects with schizophrenia. Schizophrenia is a serious psychiatric illness that affects approximately 1% of the Australian population and the research described in this proposal seeks to help understand the cause of the illness and-or to assist in the development of new drugs with which to treat the illness. T ....The research outlined in this proposal will examine the molecular make up of certain regions of the human brain and determine if components within those regions are altered in tissue from subjects with schizophrenia. Schizophrenia is a serious psychiatric illness that affects approximately 1% of the Australian population and the research described in this proposal seeks to help understand the cause of the illness and-or to assist in the development of new drugs with which to treat the illness. The goal of the research outlined in this proposal is to determine if there are changes in specific molecules in the brain, termed muscarinic receptors. The muscarinic receptors are one way that a chemical in the brain called acetylcholine can communicate with the nerve cells in the brain. Acetylcholine is known to control important functions of the brain such as in memory, cognition and learning, all of these functions are thought to be affected in schizophrenia. Importantly, the control of all these functions involve muscarinic receptors and therefore, changes in those receptors could well produce some of the symptoms of schizophrenia. We now wish to extend our early studies which suggest there may be changes in muscarinic receptors in the brain of subjects with schizophrenia to determine which of the 5 muscarinic receptors are affected in which region of the brain by the pathology of the illness. From our existing data, we would predict that these studies will add weight to the argument that muscarinic receptors are altered in schizophrenia and provide vital information as to how drugs that target these receptors may be used to treat the illness.Read moreRead less
This Senior Principal Research Fellowship will support a program of translational research and leadership for the Therapeutics Research Centre that is based at the Translational Research Institute in Brisbane and The Basil Hetzel Institute in Adelaide and for future researchers/research leaders in clinical medicine. A key research focus will be in improving the safety and efficacy of products and nanosystems, especially after application to the skin and/or absorption into the body.
Exploiting The Pharmacokinetic And Pharmacodynamic Properties Of Bile Acid Receptor Agonists To Treat Liver Disease
Funder
National Health and Medical Research Council
Funding Amount
$653,952.00
Summary
We have generated preliminary data suggesting that chemicals made by the liver, called bile acids, act on fat cells to release a hormone called adiponectin. In liver disease adiponectin has favorable effects, including reducing liver inflammation and fibrosis (scarring). By using drugs that mimic the action of bile acids we expect that adiponectin production by fat cells can be increased, creating a new way to treat patients with chronic liver diseases.
Afinity Maturation And Development Of An Anti-inflammatory Monoclonal Antibody
Funder
National Health and Medical Research Council
Funding Amount
$387,489.00
Summary
Antibodies are a relatively new class of drugs that directly target molecular mechanisms of disease. Antibody therapies, such as the breast cancer drug Herceptin, have significantly increased our arsenal of effective therapeutics. In collaboration with G2 Therapies, we will use cutting-edge genetic engineering technology to produce fully human antibodies for the treatment of inflammatory diseases, such as rheumatoid arthritis.
Innovative And Multi-disciplinary Treatment Strategies For Secondary Degeneration Following Neurotrauma
Funder
National Health and Medical Research Council
Funding Amount
$455,452.00
Summary
Following injury to the central nervous system the damage spreads into nearby areas, leading to worse outcomes for the patient. The research conducted during this Fellowship will ensure that promising treatment strategies to prevent spreading damage are used in the best way, and will determine the mechanism of action of these treatments.
Molecular & Translational Characterisation Of IMiD-Mediated BET-Protein Degradation In Multiple Myeloma
Funder
National Health and Medical Research Council
Funding Amount
$497,857.00
Summary
Thalidomide-like drugs (called IMiDs) are an essential treatment for multiple myeloma, a common incurable blood cancer. We have discovered that IMiDs destroy proteins that myeloma cells use to ‘read’ cancer-causing genes in their own DNA. We will therefore investigate how important the destruction of these ‘gene readers’ is in myeloma cells, including patient samples. This will set up future studies targeting ‘gene readers’ using IMiDs in combination with other targeted drugs in clinical trials.